151
|
R. Katritzky A, K. Hansen F, K. Beagle L, Todadze E. Efficient Microwave-Assisted Synthesis of 1,2,4-Triazole-Based Peptidomimetics Using Benzotriazole Methodology. HETEROCYCLES 2012. [DOI: 10.3987/com-11-s(p)13] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
152
|
Yeomans L, Muthu D, Lowery JJ, Martinez HN, Abrell L, Lin G, Strom K, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments. Chem Biol Drug Des 2011; 78:749-56. [PMID: 21801311 DOI: 10.1111/j.1747-0285.2011.01203.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Phosphorylation of l-serine-containing enkephalin analogs has been explored as an alternative to glycosylation in an effort to increase blood-brain barrier permeability and CNS bioavailability of peptide pharmacophores. Two enkephalin-based peptides were modified for these studies, a set related to DTLES, a mixed μ/δ-agonist, and one related to DAMGO, a highly selective μ-agonist. Each unglycosylated peptide was compared to its phosphate, its mono-benzylphosphate ester, and its β-d-glucoside. Binding was characterized in membrane preparations from Chinese hamster ovary cells expressing human μ, δ and κ-opiate receptors. Antinociception was measured in mice using the 55 °C tail-flick assay. To estimate bioavailability, the antinociceptive effect of each opioid agonist was evaluated after intracerebroventricular (i.c.v.) or intravenous administration (i.v.) of the peptides. Circular dichroism methods and high-field nuclear magnetic resonance were used in the presence and absence of sodium dodecylsulfate to understand how the presence of a membrane might influence the peptide conformations.
Collapse
Affiliation(s)
- Larisa Yeomans
- Carl S. Marvel Laboratories, Department of Chemistry and Biochemistry, BIO5, The University of Arizona, Tucson, AZ 85721, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
153
|
Gokhale A, Weldeghiorghis TK, Taneja V, Satyanarayanajois SD. Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58. J Med Chem 2011; 54:5307-19. [PMID: 21755948 DOI: 10.1021/jm200004e] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Cell adhesion molecule CD2 and its ligand CD58 provide good examples of protein-protein interactions in cells that participate in the immune response. To modulate the cell adhesion interaction, peptides were designed from the discontinuous epitopes of the β-strand region of CD2 protein. The two strands were linked by a peptide bond. β-Strands in the peptides were nucleated by inserting a β-sheet-inducing (D)-Pro-Pro sequence or a dibenzofuran (DBF) turn mimetic with key amino acid sequences from CD2 protein that binds to CD58. The solution structures of the peptides (5-10) were studied by NMR and molecular dynamics simulations. The ability of these peptides to inhibit cell adhesion interaction was studied by E-rosetting and lymphocyte epithelial assays. Peptides 6 and 7 inhibit the cell adhesion activity with an IC(50) of 7 and 11 nM, respectively, in lymphocyte epithelial adhesion assay. NMR and molecular modeling results indicated that peptides 6 and 7 exhibited β-hairpin structure in solution.
Collapse
Affiliation(s)
- Ameya Gokhale
- Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana 71201, United States
| | | | | | | |
Collapse
|
154
|
Hruby VJ, Cai M, Cain J, Nyberg J, Trivedi D. Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge. Eur J Pharmacol 2011; 660:88-93. [PMID: 21208601 PMCID: PMC3138524 DOI: 10.1016/j.ejphar.2010.10.109] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2010] [Revised: 10/05/2010] [Accepted: 10/16/2010] [Indexed: 11/22/2022]
Abstract
The major pharmacophore for the melanocortin 1, 3, 4 and 5 receptors is the sequence -His-Phe-Arg-Trp-. There is a need for potent, biologically stable, receptor selective ligands, both agonists and antagonists, for these receptors. In this report we briefly examine the structural and biophysical approaches we have taken to develop selective agonist and antagonist ligands that can cross (or not) the blood brain barrier. Remaining questions and unmet needs are also discussed.
Collapse
Affiliation(s)
- Victor J Hruby
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
| | | | | | | | | |
Collapse
|
155
|
Cai M, Liu Z, Qu H, Fan H, Zheng Z, Hruby VJ. Utilize conjugated melanotropins for the earlier diagnosis and treatment of melanoma. Eur J Pharmacol 2011; 660:188-93. [PMID: 21315067 PMCID: PMC3095766 DOI: 10.1016/j.ejphar.2011.01.032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2010] [Revised: 12/22/2010] [Accepted: 01/13/2011] [Indexed: 01/03/2023]
Abstract
Peptides serve as effective drugs and contrast agents in the clinic today. However the inherent drawbacks of peptide structures can limit their efficacy as drugs. To overcome this we have been developing new methods to create 'tailor-made' peptides and peptide mimetics with improved pharmacological and physical properties. In this work we introduce novel peptide and small molecule conjugated molecules for earlier diagnosis and treatment of melanoma.
Collapse
Affiliation(s)
- Minying Cai
- Department of Chemistry and Biochemistry, Tucson, Arizona 85721 U.S.A
| | - Zhonglin Liu
- Department of Radiology, University of Arizona, Tucson, Arizona 85721 U.S.A
| | - Hongchang Qu
- Department of Chemistry and Biochemistry, Tucson, Arizona 85721 U.S.A
| | - Helen Fan
- Department of Radiology, University of Arizona, Tucson, Arizona 85721 U.S.A
| | - Zhiping Zheng
- Department of Chemistry and Biochemistry, Tucson, Arizona 85721 U.S.A
| | - Victor J. Hruby
- Department of Chemistry and Biochemistry, Tucson, Arizona 85721 U.S.A
| |
Collapse
|
156
|
Su L, Fang H, Xu W. Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 - 2010): a patent review. Expert Opin Ther Pat 2011; 21:1241-65. [PMID: 21619485 DOI: 10.1517/13543776.2011.587002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. AREAS COVERED In this review, APN inhibitors in the patents publicized during 2006 - 2010 are introduced. Readers will gain information on the patent inhibitors, including chemical structures, original sources or synthetic methods, biological assays and application potential. EXPERT OPINION It is difficult to identify compounds that interact with the function not relevant with peptide-hydrolysis of APN in the enzyme activity assay, and such compounds have not been reported in the patents during the past 5 years. The progress of protein-small molecule interaction detecting means, such as surface plasmon resonance, will possibly help develop such compounds for the treatment of relevant diseases or new molecular probes in mechanism investigation.
Collapse
Affiliation(s)
- Li Su
- Shandong University, School of Pharmaceutical Sciences, Department of Medicinal Chemistry, Ji’nan, Shandong, PR China
| | | | | |
Collapse
|
157
|
Macaluso NJM, Pitkin SL, Maguire JJ, Davenport AP, Glen RC. Discovery of a competitive apelin receptor (APJ) antagonist. ChemMedChem 2011; 6:1017-23. [PMID: 21560248 DOI: 10.1002/cmdc.201100069] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2011] [Revised: 03/29/2011] [Indexed: 01/27/2023]
Abstract
The apelin receptor (APJ) is a class A G-protein-coupled receptor (GPCR) and is a putative target for the treatment of cardiovascular and metabolic diseases. Apelin-13 (NH₂-QRPRLSHKGPMPF-COOH) is a vasoactive peptide and one of the most potent endogenous inotropic agents identified to date. We report the design and discovery of a novel APJ antagonist. By using a bivalent ligand approach, we have designed compounds with two 'affinity' motifs and a short series of linker groups with different conformational and non-bonded interaction properties. One of these, cyclo(1-6)CRPRLC-KH-cyclo(9-14)CRPRLC is a competitive antagonist at APJ. Radioligand binding in CHO cells transfected with human APJ gave a K(i) value of 82 nM, competition binding in human left ventricle gave a K(D) value of 3.2 μM, and cAMP accumulation assays in CHO-K1-APJ cells gave a K(D) value of 1.32 μM.
Collapse
Affiliation(s)
- N J Maximilian Macaluso
- Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of Cambridge, Lensfield Road CB2 1EW, Cambridge, UK
| | | | | | | | | |
Collapse
|
158
|
Wu X, Park PK, Danishefsky SJ. On the synthesis of conformationally modified peptides through isonitrile chemistry: implications for dealing with polypeptide aggregation. J Am Chem Soc 2011; 133:7700-3. [PMID: 21539308 DOI: 10.1021/ja2023898] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A method for introducing a dimethyleneoxy constraint joining the N atoms of two consecutive amino acids in the context of a polypeptide has been developed. This constraint can profoundly affect the tendency of a polypeptide to suffer aggregation and desolubilization, and it can be readily removed under mild conditions.
Collapse
Affiliation(s)
- Xiangyang Wu
- Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10065, USA
| | | | | |
Collapse
|
159
|
Wu Z, Hruby VJ. Backbone alignment modeling of the structure-activity relationships of opioid ligands. J Chem Inf Model 2011; 51:1151-64. [PMID: 21488692 DOI: 10.1021/ci2000852] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Opioid studies are an important area of modern medicinal chemistry research. In this study we have provided innovative considerations to some long-standing problems in opioid studies, specifically the opioid pharmacophore and the potential binding modes of opioid ligands. Based on a new peptide backbone-alignment concept that we have developed along with this study, we discuss a wide variety of opioid ligands with respect to their structure-activity relationships.
Collapse
Affiliation(s)
- Zhijun Wu
- ABC Resources , Plainsboro, New Jersey 08536, United States
| | | |
Collapse
|
160
|
Crossing borders to bind proteins--a new concept in protein recognition based on the conjugation of small organic molecules or short peptides to polypeptides from a designed set. Anal Bioanal Chem 2011; 400:1653-64. [PMID: 21461620 PMCID: PMC3093540 DOI: 10.1007/s00216-011-4905-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Revised: 03/10/2011] [Accepted: 03/12/2011] [Indexed: 02/05/2023]
Abstract
A new concept for protein recognition and binding is highlighted. The conjugation of small organic molecules or short peptides to polypeptides from a designed set provides binder molecules that bind proteins with high affinities, and with selectivities that are equal to those of antibodies. The small organic molecules or peptides need to bind the protein targets but only with modest affinities and selectivities, because conjugation to the polypeptides results in molecules with dramatically improved binder performance. The polypeptides are selected from a set of only sixteen sequences designed to bind, in principle, any protein. The small number of polypeptides used to prepare high-affinity binders contrasts sharply with the huge libraries used in binder technologies based on selection or immunization. Also, unlike antibodies and engineered proteins, the polypeptides have unordered three-dimensional structures and adapt to the proteins to which they bind. Binder molecules for the C-reactive protein, human carbonic anhydrase II, acetylcholine esterase, thymidine kinase 1, phosphorylated proteins, the D-dimer, and a number of antibodies are used as examples to demonstrate that affinities are achieved that are higher than those of the small molecules or peptides by as much as four orders of magnitude. Evaluation by pull-down experiments and ELISA-based tests in human serum show selectivities to be equal to those of antibodies. Small organic molecules and peptides are readily available from pools of endogenous ligands, enzyme substrates, inhibitors or products, from screened small molecule libraries, from phage display, and from mRNA display. The technology is an alternative to established binder concepts for applications in drug development, diagnostics, medical imaging, and protein separation.
Collapse
|
161
|
Hruby VJ, Cai M, Nyberg J, Muthu D. Approaches to the rational design of selective melanocortin receptor antagonists. Expert Opin Drug Discov 2011; 6:543-57. [PMID: 22646078 DOI: 10.1517/17460441.2011.565743] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION When establishing the physiological roles of specific receptors in normal and disease states, it is critical to have selective antagonist ligands for each receptor in a receptor system with several subtypes. The melanocortin receptors have five subtypes referred to as the melanocortin 1 receptor, melanocortin 2 receptor, melanocortin 3 receptor, melanocortin 4 receptor and melanocortin 5 receptor, and they are of critical importance for many aspects of human health and disease. AREAS COVERED This article reviews the current efforts to design selective antagonistic ligands for the five human melanocortin receptors summarizing the currently published orthosteric and allosteric antagonists for each of these receptors. EXPERT OPINION Though there has been progress, there are still few drugs available that address the many significant biological activities and diseases that are associated with these receptors, which is possibly due to the lack of receptor selectivity that these designed ligands are currently showing. The authors believe that further studies into the antagonists' 3D conformational and topographical properties in addition to future mutagenesis studies will provide greater insight into these ligands which could play a role in the treatment of various diseases in the future.
Collapse
Affiliation(s)
- Victor J Hruby
- University of Arizona, Department of Chemistry and Biochemistry , 1306 E. University Blvd., Tucson, AZ 85721 , USA
| | | | | | | |
Collapse
|
162
|
Duffy FJ, Verniere M, Devocelle M, Bernard E, Shields DC, Chubb AJ. CycloPs: generating virtual libraries of cyclized and constrained peptides including nonnatural amino acids. J Chem Inf Model 2011; 51:829-36. [PMID: 21434641 DOI: 10.1021/ci100431r] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We introduce CycloPs, software for the generation of virtual libraries of constrained peptides including natural and nonnatural commercially available amino acids. The software is written in the cross-platform Python programming language, and features include generating virtual libraries in one-dimensional SMILES and three-dimensional SDF formats, suitable for virtual screening. The stand-alone software is capable of filtering the virtual libraries using empirical measurements, including peptide synthesizability by standard peptide synthesis techniques, stability, and the druglike properties of the peptide. The software and accompanying Web interface is designed to enable the rapid generation of large, structurally diverse, synthesizable virtual libraries of constrained peptides quickly and conveniently, for use in virtual screening experiments. The stand-alone software, and the Web interface for evaluating these empirical properties of a single peptide, are available at http://bioware.ucd.ie .
Collapse
Affiliation(s)
- Fergal J Duffy
- UCD Complex and Applied Systems Laboratory, Conway Institute of Biomolecular and Biomedical Sciences, and School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland.
| | | | | | | | | | | |
Collapse
|
163
|
Gruber CW, Muttenthaler M, Freissmuth M. Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. Curr Pharm Des 2011; 16:3071-88. [PMID: 20687879 DOI: 10.2174/138161210793292474] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2010] [Accepted: 07/21/2010] [Indexed: 01/20/2023]
Abstract
G protein-coupled receptors (GPCRs) are considered to represent the most promising drug targets; it has been repeatedly said that a large fraction of the currently marketed drugs elicit their actions by binding to GPCRs (with cited numbers varying from 30-50%). Closer scrutiny, however, shows that only a modest fraction of (≈60) GPCRs are, in fact, exploited as drug targets, only ≈20 of which are peptide-binding receptors. The vast majority of receptors in the humane genome have not yet been explored as sites of action for drugs. Given the drugability of this receptor class, it appears that opportunities for drug discovery abound. In addition, GPCRs provide for binding sites other than the ligand binding sites (referred to as the "orthosteric site"). These additional sites include (i) binding sites for ligands (referred to as "allosteric ligands") that modulate the affinity and efficacy of orthosteric ligands, (ii) the interaction surface that recruits G proteins and arrestins, (iii) the interaction sites of additional proteins (GIPs, GPCR interacting proteins that regulate G protein signaling or give rise to G protein-independent signals). These sites can also be targeted by peptides. Combinatorial and natural peptide libraries are therefore likely to play a major role in identifying new GPCR ligands at each of these sites. In particular the diverse natural peptide libraries such as the venom peptides from marine cone-snails and plant cyclotides have been established as a rich source of drug leads. High-throughput screening and combinatorial chemistry approaches allow for progressing from these starting points to potential drug candidates. This will be illustrated by focusing on the ligand-based drug design of oxytocin (OT) and vasopressin (AVP) receptor ligands using natural peptide leads as starting points.
Collapse
Affiliation(s)
- Christian W Gruber
- Institute of Pharmacology, Center of Biomolecular Medicine & Pharmacology, Medical University of Vienna, Waehringer Str. 13a, A-1090 Vienna, Austria
| | | | | |
Collapse
|
164
|
Challenges in optimizing a prostate carcinoma binding peptide, identified through the phage display technology. Molecules 2011; 16:1559-78. [PMID: 21321528 PMCID: PMC6259618 DOI: 10.3390/molecules16021559] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2010] [Revised: 02/09/2011] [Accepted: 02/11/2011] [Indexed: 11/17/2022] Open
Abstract
The transfer of peptides identified through the phage display technology to clinical applications is difficult. Major drawbacks are the metabolic degradation and label instability. The aim of our work is the optimization of DUP-1, a peptide which was identified by phage display to specifically target human prostate carcinoma. To investigate the influence of chelate conjugation, DOTA was coupled to DUP-1 and labeling was performed with ¹¹¹In. To improve serum stability cyclization of DUP-1 and targeted D-amino acid substitution were carried out. Alanine scanning was performed for identification of the binding site and based on the results peptide fragments were chemically synthesized. The properties of modified ligands were investigated in in vitro binding and competition assays. In vivo biodistribution studies were carried out in mice, carrying human prostate tumors subcutaneously. DOTA conjugation resulted in different cellular binding kinetics, rapid in vivo renal clearance and increased tumor-to-organ ratios. Cyclization and D-amino acid substitution increased the metabolic stability but led to binding affinity decrease. Fragment investigation indicated that the sequence NRAQDY might be significant for target-binding. Our results demonstrate challenges in optimizing peptides, identified through phage display libraries, and show that careful investigation of modified derivatives is necessary in order to improve their characteristics.
Collapse
|
165
|
Banappagari S, Ronald S, Satyanarayanajois SD. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. MEDCHEMCOMM 2011; 2:752-759. [PMID: 21887403 DOI: 10.1039/c1md00126d] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Human epidermal growth factor receptor 2 (HER2) is a member of the human epidermal growth factor receptor kinases and is involved in a signaling cascade for cell growth and differentiation. It is well established that HER2-mediated heterodimerization has important implications in cancer. Deregulation of signaling pathways and overexpression of HER2 is known to occur in cancer cells, indicating the role of HER2 in tumorigenesis. Therefore, blocking HER2-mediated signaling has potential therapeutic value. We have designed several peptidomimetics to inhibit HER2-mediated signaling for cell growth. One of the compounds (compound 5, Arg-[3-amino-3(1-napthyl)-propionic acid]-Phe) exhibited antiproliferative activity with IC(50) values in the nanomolar to micromolar range in breast cancer cell lines. To further investigate the structure-activity relationship of the compounds, various analogs of compound 5 were designed. Conformational constraints were initiated in the peptidomimetic with introduction of a Pro residue in the peptidomimetic sequence. Results of antiproliferative activity indicated that analogs of compound 5 with C-and N-terminal ends capped (compound 16) and compound 9 with Asp at the C-terminal exhibited antiproliferative activity in the lower micromolar range against breast cancer cell lines. Introduction of conformational constraints such as Pro residue in the sequence or cyclization did not enhance the activity of the peptidomimetic. Competitive binding studies were carried out to evaluate the binding of potent peptidomimetics to HER2-overexpressing cancer cell lines. Results indicated that compounds exhibiting antiproliferative activity in breast cancer cell lines bind to the cells that overexpress HER2 protein.
Collapse
Affiliation(s)
- Sashikanth Banappagari
- Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201
| | | | | |
Collapse
|
166
|
Abstract
Numerous methods have recently been developed to characterize cells for size, shape, and specific cell-surface markers. Most of these methods rely upon exogenous labeling of the cells and are better suited for large cell populations (>10,000). Here, we review a label-free method of characterizing and screening cells based on the Coulter-counter technique of particle sizing: an individual cell transiting a microchannel (or "pore") causes a downward pulse in the measured DC current across that "pore". Pulse magnitude corresponds to the cell size, pulse width to the transit time needed for the cell to pass through the pore, and pulse shape to how the cell traverses across the pore (i.e., rolling or tumbling). When the pore is functionalized with an antibody that is specific to a surface-epitope of interest, label-free screening of a specific marker is possible, as transient binding between the two results in longer time duration than when the pore is unfunctionalized or functionalized with a nonspecific antibody. While this method cannot currently compete with traditional technology in terms of throughput, there are a number of applications for which this technology is better suited than current commercial cytometry systems. Applications include the rapid and nondestructive analysis of small cell populations (<100), which is not possible with current technology, and a platform for providing true point-of-care clinical diagnostics, due to the simplicity of the device, low manufacturing costs, and ease of use.
Collapse
Affiliation(s)
- M R Chapman
- Biophysics Graduate Group, Department of Mechanical Engineering, University of California, Berkeley, California, USA
| | | |
Collapse
|
167
|
Muttenthaler M, Andersson A, de Araujo AD, Dekan Z, Lewis RJ, Alewood PF. Modulating Oxytocin Activity and Plasma Stability by Disulfide Bond Engineering. J Med Chem 2010; 53:8585-96. [DOI: 10.1021/jm100989w] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Markus Muttenthaler
- Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, 4072 St. Lucia, Brisbane, Queensland
| | - Asa Andersson
- Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, 4072 St. Lucia, Brisbane, Queensland
| | - Aline D. de Araujo
- Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, 4072 St. Lucia, Brisbane, Queensland
| | - Zoltan Dekan
- Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, 4072 St. Lucia, Brisbane, Queensland
| | - Richard J. Lewis
- Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, 4072 St. Lucia, Brisbane, Queensland
| | - Paul F. Alewood
- Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Road, 4072 St. Lucia, Brisbane, Queensland
| |
Collapse
|
168
|
Caporale A, Schievano E, Peggion E. Peptide-peptoid hybrids based on (1-11)-parathyroid hormone analogs. J Pept Sci 2010; 16:480-5. [PMID: 20629116 DOI: 10.1002/psc.1265] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A series of peptide-peptoid hybrids, containing N-substituted glycines, were synthesized based on the H-Aib-Val-Aib-Glu-Ile-Gln-Leu-Nle-His-Gln-Har-NH(2) (Har = Homoarginine) as the parent parathyroid hormone (1-11) analog. The compounds were pharmacologically characterized in their agonistic activity at the parathyroid hormone 1 receptor.
Collapse
Affiliation(s)
- A Caporale
- Department of Chemical Sciences, Institute of Biomolecular Chemistry, CNR, University of Padova, Padova, Italy.
| | | | | |
Collapse
|
169
|
Nefzi A, Arutyunyan S, Fenwick JE. Two-step Hantzsch based macrocyclization approach for the synthesis of thiazole-containing cyclopeptides. J Org Chem 2010; 75:7939-41. [PMID: 21033717 DOI: 10.1021/jo1016822] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Macrocyclization via an efficient high-yielding solid-phase intramolecular thioalkylation reaction is described. The reaction of S-nucleophiles with newly generated N-terminal 4-chloromethyl thiazoles led to the desired macrocyclization products 5 in high purities and good overall yields.
Collapse
Affiliation(s)
- Adel Nefzi
- Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port Saint Lucie, Florida 34987, United States
| | | | | |
Collapse
|
170
|
Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010; 110:3087-111. [PMID: 20225899 DOI: 10.1021/cr900361p] [Citation(s) in RCA: 253] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Seulki Lee
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 31 Center Drive, Suite 1C14, Bethesda, Maryland 20892-2281, USA
| | | | | |
Collapse
|
171
|
Green BR, White KL, McDougle DR, Zhang L, Klein B, Scholl EA, Pruess TH, White HS, Bulaj G. Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities. J Pept Sci 2010; 16:486-95. [DOI: 10.1002/psc.1266] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
172
|
|
173
|
Satyanarayanajois SD, Büyüktimkin B, Gokhale A, Ronald S, Siahaan TJ, Latendresse JR. A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse model. Chem Biol Drug Des 2010; 76:234-44. [PMID: 20572813 DOI: 10.1111/j.1747-0285.2010.01001.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Cell adhesion molecules play a central role at every step of the immune response. The function of leukocytes can be regulated by modulating adhesion interactions between cell adhesion molecules to develop therapeutic agents against autoimmune diseases. Among the different cell adhesion molecules that participate in the immunologic response, CD2 and its ligand CD58 (LFA-3) are two of the best-characterized adhesion molecules mediating the immune response. To modulate the cell adhesion interaction, peptides were designed from the discontinuous epitopes of the beta-strand region of CD2 protein. The two strands were linked by a peptide bond. beta-Strands in the peptides were nucleated by inserting a beta-sheet-inducing Pro-Gly sequence with key amino acid sequences from CD2 protein that binds to CD58. Using a fluorescence assay, peptides that exhibited potential inhibitory activity in cell adhesion were evaluated for their ability to bind to CD58 protein. A model for peptide binding to CD58 protein was proposed based on docking studies. Administration of one of the peptides, P3 in collagen-induced arthritis in the mouse model, indicated that peptide P3 was able to suppress rheumatoid arthritis in mice.
Collapse
Affiliation(s)
- Seetharama D Satyanarayanajois
- Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
| | | | | | | | | | | |
Collapse
|
174
|
Molina L, Moreno-Clavijo E, Moreno-Vargas AJ, Carmona AT, Robina I. New Methodology for the Stereoselective Synthesis of α-Furfurylamines from Sugars: Application to the Synthesis of Furyl Amino Acids and 3-Furylisoserines. European J Org Chem 2010. [DOI: 10.1002/ejoc.201000183] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
175
|
Abstract
Targeted molecular imaging techniques have become indispensable tools in modern diagnostics because they provide accurate and specific diagnosis of disease information. Conventional nonspecific contrast agents suffer from low targeting efficiency; thus, the use of molecularly targeted imaging probes is needed depending on different imaging modalities. Although recent technologies have yielded various strategies for designing smart probes, utilization of peptide-based probes has been most successful. Phage display technology and combinatorial peptide chemistry have profoundly impacted the pool of available targeting peptides for the efficient and specific delivery of imaging labels. To date, selected peptides that target a variety of disease-related receptors and biomarkers are in place. These targeting peptides can be coupled with the appropriate imaging moieties or nanoplatforms on demand with the help of sophisticated bioconjugation or radiolabeling techniques. This review article examines the current trends in peptide-based imaging probes developed for in vivo applications. We discuss the advantage of and challenges in developing peptide-based probes and summarize current systems with respect to their unique design strategies and applications.
Collapse
Affiliation(s)
- Seulki Lee
- Laboratory for Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 31 Center Drive, Suite 1C14, Bethesda, Maryland 20892-2281, USA
| | | | | |
Collapse
|
176
|
Mizukoshi Y, Nagasu M, Shimada I, Takahashi H. Precise structural determination of weakly binding peptides by utilizing dihedral angle constraints. JOURNAL OF BIOMOLECULAR NMR 2010; 46:299-305. [PMID: 20229289 DOI: 10.1007/s10858-010-9402-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2009] [Accepted: 02/24/2010] [Indexed: 05/28/2023]
Abstract
Structural determination of target-bound conformations of peptides is of primary importance for the optimization of peptide ligands and peptide-mimetic design. In the structural determination of weakly binding ligands, transferred nuclear Overhauser effect (TrNOE) methods have been widely used. However, not many distance constraints can be obtained from small peptide ligands by TrNOE, especially for peptides bound to a target molecule in an extended conformation. Therefore, for precise structural determination of weakly binding peptides, additional structural constraints are required. Here, we present a strategy to systematically introduce dihedral angle constraints obtained from multiple transferred cross-correlated relaxation experiments and demonstrate precise structures of weakly binding peptides. As a result, we could determine the bioactive conformations of phage-derived peptide ligands and define their core binding motifs.
Collapse
Affiliation(s)
- Yumiko Mizukoshi
- Biomedicinal Information Research Center, National Institute of Advanced Industrial Science and Technology, Aomi 2-41-6, Koto-ku, Tokyo, 135-0064, Japan
| | | | | | | |
Collapse
|
177
|
Structure-Activity Relationships (SAR) of Melanocortin and Agouti-Related (AGRP) Peptides. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 681:1-18. [DOI: 10.1007/978-1-4419-6354-3_1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/25/2023]
|
178
|
Abstract
From a scientific perspective, efforts to understand biology including what constitutes health and disease has become a chemical problem. However, chemists and biologists "see" the problems of understanding biology from different perspectives, and this has retarded progress in solving the problems especially as they relate to health and disease. This suggests that close collaboration between chemists and biologists is not only necessary but essential for progress in both the biology and chemistry that will provide solutions to the global questions of biology. This perspective has directed my scientific efforts for the past 45 years, and in this overview I provide my perspective of how the applications of synthetic chemistry, structural design, and numerous other chemical principles have intersected in my collaborations with biologists to provide new tools, new science, and new insights that were only made possible and fruitful by these collaborations.
Collapse
Affiliation(s)
- Victor J Hruby
- Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, USA.
| |
Collapse
|
179
|
Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry. Future Med Chem 2009; 1:1289-310. [DOI: 10.4155/fmc.09.97] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Although not complying with Lipinski’s rule, peptides are to an increasing extent being developed into new active pharmaceutical ingredients. This is mainly due to novel application routes, formulations and chemical modifications, which confer on the peptides improved uptake and increased metabolic stability. A brief survey of currently approved peptide drugs and the present scope of the application of peptides as drugs is provided. Cyclic peptides are emerging as an interesting class of peptides with conformational rigidity and homogeneity, high receptor affinity and selectivity, increased metabolic stability and – in special cases – even oral availability. Challenges and new methodology for the synthesis of cyclic peptides are outlined and an overview of approaches toward the design of peptide conformation and peptide modification by nonproteinogenic building blocks is given.
Collapse
|
180
|
Odagami T, Tsuda Y, Kogami Y, Kouji H, Okada Y. Identification of new agonists of urotensin-II from a cyclic peptide library. Bioorg Med Chem 2009; 17:6742-7. [DOI: 10.1016/j.bmc.2009.07.058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2009] [Revised: 07/17/2009] [Accepted: 07/21/2009] [Indexed: 10/20/2022]
|
181
|
Operationally convenient asymmetric synthesis of (S)-2-amino-3,3-bis-(4-fluorophenyl)propanoic acid. J Fluor Chem 2009. [DOI: 10.1016/j.jfluchem.2009.03.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
182
|
Bourgault S, Vaudry D, Ségalas-Milazzo I, Guilhaudis L, Couvineau A, Laburthe M, Vaudry H, Fournier A. Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem 2009; 52:3308-16. [PMID: 19413310 DOI: 10.1021/jm900291j] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PAC1 receptor is abundant in the CNS and plays an important role in neuronal survival. To identify the molecular determinants and the conformational components responsible for the activation of the PAC1 receptor, we performed a SAR study focusing on the N-terminal domain of its endogenous ligand, PACAP. This approach revealed that residues Asp(3) and Phe(6) are key elements of the pharmacophore of the PAC1 receptor. This study, supported by NMR structural analyses, suggests that the N-terminal tail of PACAP (residues 1 to 4) adopts a specific conformation similar to a turn when it activates the PAC1 receptor. Moreover, the integrity of the alpha-helix conformation observed at positions 5 to 7 appears crucial to allow the binding of PACAP. Characterization of analogues led to the identification of several superagonists, such as [Bip(6)]PACAP27, and of a new potent PAC1 receptor antagonist, [Sar(4)]PACAP38. The bioactive conformation inferred from this SAR study could constitute an appropriate molecular scaffold supporting the design of nonpeptidic PAC1 receptor agonists.
Collapse
Affiliation(s)
- Steve Bourgault
- INRS-Institut Armand-Frappier, Institut National de la Recherche Scientifique, 531 boulevard des Prairies, Laval, Quebec H7V 1B7, Canada
| | | | | | | | | | | | | | | |
Collapse
|
183
|
Grieco P, Carotenuto A, Campiglia P, Gomez-Monterrey I, Auriemma L, Sala M, Marcozzi C, d’Emmanuele di Villa Bianca R, Brancaccio D, Rovero P, Santicioli P, Meini S, Maggi CA, Novellino E. New Insight into the Binding Mode of Peptide Ligands at Urotensin-II Receptor: Structure−Activity Relationships Study on P5U and Urantide. J Med Chem 2009; 52:3927-40. [DOI: 10.1021/jm900148c] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Paolo Grieco
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Alfonso Carotenuto
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Pietro Campiglia
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Isabel Gomez-Monterrey
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Luigia Auriemma
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Marina Sala
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Cristina Marcozzi
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Roberta d’Emmanuele di Villa Bianca
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Diego Brancaccio
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Paolo Rovero
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Paolo Santicioli
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Stefania Meini
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Carlo A. Maggi
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| | - Ettore Novellino
- Department of Pharmaceutical and Toxicological Chemistry, University of Naples “Federico II”, Via D. Montesano, I-80131 Naples, Italy, Laboratorio Interdipartimentale di Chimica e Biologia dei Peptidi e Proteine, Department di Scienze Farmaceutiche, Università di Firenze, I-50019 Sesto Fiorentino, Florence, Italy, Department of Experimental Pharmacology, University of Naples “Federico II”, I-80131 Naples, Italy, Department of Pharmacology, Menarini Ricerche, Via Rismpondo 12/A, I-50131 Florence, Italy,
| |
Collapse
|
184
|
Giddu S, Subramanian V, Yoon HS, Satyanarayanajois SD. Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem 2009; 52:726-36. [PMID: 19123855 DOI: 10.1021/jm8008212] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The CD2-CD58 interaction in immune regulation and disease pathology has provided new targets for developing potential immunosuppressive agents. In the present study, we report the introduction of constraints to generate beta-hairpin structures from the strand sequences of CD2 protein. The beta-hairpin structures were induced in the designed peptides by introducing Pro-Gly sequences in the peptides. Results from NMR and MD simulation indicated that the peptides exhibited beta-turn structure at the X-Pro-Gly-Y sequence and formed the beta-hairpin structure in solution. The ability of these peptides to inhibit cell adhesion was evaluated by two cell adhesion assays. Among the peptides studied (1-4) (P1-P4), peptides 2-4 were able to inhibit cell adhesion between Jurkat cells and SRBC nearly 50% at 180 microM, and 80% inhibition between Jurkat cells and Caco-2 cells was seen at 90 microM. Peptide 1 did not show significant inhibition activity compared to control.
Collapse
Affiliation(s)
- Sumana Giddu
- Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Avenue, Monroe, Louisiana 71209, USA
| | | | | | | |
Collapse
|
185
|
Zimmermann TJ, Niesen FH, Pilka ES, Knapp S, Oppermann U, Maier ME. Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. Bioorg Med Chem 2009; 17:530-6. [DOI: 10.1016/j.bmc.2008.11.076] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2008] [Revised: 11/26/2008] [Accepted: 11/29/2008] [Indexed: 11/26/2022]
|
186
|
Lin J, Liao S, Hruby VJ. Syntheses of optically pure, conformationally constrained, and highly hydrophobic unusual amino acids: 2-amino-3, 3-diarylpropionic acids*. ACTA ACUST UNITED AC 2008; 65:105-12. [PMID: 15686541 DOI: 10.1111/j.1399-3011.2004.00194.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A series of optically pure, conformationally constrained, and highly hydrophobic unusual aromatic amino acids, 2-amino-3,3-diarylpropionic acids, were synthesized via asymmetric 1,4-Michael addition reaction/azidation reactions in seven steps with overall yields of 20-30%.
Collapse
Affiliation(s)
- J Lin
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | | | | |
Collapse
|
187
|
Monga V, Meena CL, Kaur N, Kumar S, Pawar C, Sharma SS, Jain R. Facile synthesis ofN-α-boc-1,2-dialkyl-l-histidines: Utility in the synthesis of thyrotropin-releasing hormone (trh) analogs and evaluation of the cns activity. J Heterocycl Chem 2008. [DOI: 10.1002/jhet.5570450608] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
188
|
Preto MAC, Melo A, Rodrigues LM, Maia HLS, Ramos MJ. Structural insight on the activity of type 1 angiotensin II peptide antagonists using MD simulations. J Phys Chem B 2008; 112:13620-8. [PMID: 18834172 DOI: 10.1021/jp802349w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Angiotensin II (AngII) is an octapeptide hormone, which plays a very important role in the blood pressure control mechanism. The excess production of this hormone is one of the main causes of hypertension illness. The antagonists for AngII At1 receptor constitute some of the most effective antihypertension drugs. In this work, both tested type1 AngII antagonists as well as new modeled antagonists (obtained by substitution of nonspecific amino acids by noncode residues (Sarcosine (Sar) and several Calpha, Calpha-dialkylglycines)) were simulated in dimethyl sulfoxide (DMSO) using molecular dynamics (MD). A number of common structural characteristics were identified on the active (and potentially active) simulated analogs, which seem to be correlated with their antagonistic activity. Two of the designed analogs were proposed as possible antagonists.
Collapse
Affiliation(s)
- Marco A C Preto
- Departamento de Química, Universidade do Minho, Gualtar, 4710-057 Braga, Portugal
| | | | | | | | | |
Collapse
|
189
|
Zintsmaster JS, Wilson BD, Peng JW. Dynamics of ligand binding from 13C NMR relaxation dispersion at natural abundance. J Am Chem Soc 2008; 130:14060-1. [PMID: 18834120 DOI: 10.1021/ja805839y] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We show that Carr-Purcell-Meiboom-Gill (CPMG) 13Calpha NMR relaxation dispersion measurements are a viable means for profiling mus-ms ligand dynamics involved in receptor binding. Critically, the dispersion is at natural 13C abundance; this matches typical pharmaceutical research settings in which ligand isotope-labeling is often impractical. The dispersion reveals ligand 13Calpha nuclei that experience mus-ms modulation of their chemical shifts due to binding. 13Calpha shifts are dominated by local torsion angles , psi, chi1; hence, these experiments identify flexible torsion angles that may assist complex formation. Since the experiments detect the ligand, they are viable even in the absence of a receptor structure. The mus-ms dynamic information gained helps establish flexibility-activity relationships. We apply these experiments to study the binding of a phospho-peptide substrate ligand to the peptidyl-prolyl isomerase Pin1.
Collapse
Affiliation(s)
- John S Zintsmaster
- Department of Chemistry and Biochemistry, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, Indiana 46556, USA
| | | | | |
Collapse
|
190
|
Walker MA. Treatment of autism spectrum disorders: neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets. Expert Opin Ther Targets 2008; 12:949-67. [PMID: 18620518 DOI: 10.1517/14728222.12.8.949] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND There is a growing body of literature describing the etiology of autism spectrum disorders (ASD). Some of the targets suggested belong to neurochemical transmitter pathways implicated in the behavior and motivation reward pathway. OBJECTIVE To examine data linking potential targets to ASD and the feasibility of developing drugs targeting these pathways. While the inhibitors are mostly being developed for other indications, it is beneficial to examine them to determine the responsiveness of the targets to small-molecule modulation. METHODS A search in Medline and Scifinder for articles concerning relevant targets in the context of ASD and their relation to the reward signaling pathway. RESULTS There is evidence suggesting that behaviors controlled by these targets are related to behaviors exhibited by individuals with ASD. The targets appear to be involved in neurotransmitter pathways controlling motivation and reward, further implicating this system in ASD. Sufficient research has been conducted to identify lead compounds for discovering agents for treatment of ASD.
Collapse
Affiliation(s)
- Michael A Walker
- Bristol-Myers Squibb Co., Medicinal Chemistry, Research and Development, Wallingford, CT, USA.
| |
Collapse
|
191
|
Carbonaro A, Mohanty SK, Huang H, Godley LA, Sohn LL. Cell characterization using a protein-functionalized pore. LAB ON A CHIP 2008; 8:1478-1485. [PMID: 18818802 DOI: 10.1039/b801929k] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
We demonstrate a highly-sensitive and label-free method for characterizing cells based on cell-surface receptors. The method involves measuring a current pulse generated when an individual cell passes through an artificial pore. When the pore is functionalized with proteins, specific interactions between a cell-surface marker and the functionalized proteins retard the cell, thus leading to an increased pulse duration that indicates the presence of that specific biomarker. For proof-of-principle, we successfully screened murine erythroleukemia cells based on their CD34 surface marker in both a single and mixed population of cells. Further, we developed a unified constrained statistical model for estimating the ratios of cells in a mixed population. Finally, we demonstrated our ability to screen a small number of cells (hundreds or less) with high accuracy and sensitivity. Overall, our pore-based method is broadly applicable and, in the future, could provide a full range of in vitro cell-based assays.
Collapse
Affiliation(s)
- Andrea Carbonaro
- Dept. of Mechanical Engineering, University of California at Berkeley, Berkeley, CA 94720-1740, USA
| | | | | | | | | |
Collapse
|
192
|
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 2008; 7:694-710. [DOI: 10.1038/nrd2572] [Citation(s) in RCA: 284] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
193
|
Buku A, Keselman I, Lupyan D, Mezei M, Price JA. Effective Mast Cell Degranulating Peptide Inhibitors of the IgE/FcɛRI Receptor Interaction. Chem Biol Drug Des 2008; 72:133-9. [DOI: 10.1111/j.1747-0285.2008.00684.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
194
|
Udugamasooriya DG, Spaller MR. Conformational constraint in protein ligand design and the inconsistency of binding entropy. Biopolymers 2008; 89:653-67. [DOI: 10.1002/bip.20983] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
195
|
Williams G, Wood A, Williams EJ, Gao Y, Mercado ML, Katz A, Joseph-McCarthy D, Bates B, Ling HP, Aulabaugh A, Zaccardi J, Xie Y, Pangalos MN, Walsh FS, Doherty P. Ganglioside Inhibition of Neurite Outgrowth Requires Nogo Receptor Function. J Biol Chem 2008; 283:16641-52. [DOI: 10.1074/jbc.m802067200] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
196
|
Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem 2008; 16:6924-35. [PMID: 18556208 DOI: 10.1016/j.bmc.2008.05.046] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2008] [Revised: 05/09/2008] [Accepted: 05/22/2008] [Indexed: 01/28/2023]
Abstract
Analogues of the hexapeptide angiotensin IV (Ang IV, Val(1)-Tyr(2)-Ile(3)-His(4)-Pro(5)-Phe(6)) encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr(2) and a phenylacetic or benzoic acid moiety replacing His(4)-Pro(5)-Phe(6) have been synthesized and evaluated in biological assays. The analogues inhibited the proteolytic activity of cystinyl aminopeptidase (CAP), frequently referred to as the insulin-regulated aminopeptidase (IRAP), and were found less efficient as inhibitors of aminopeptidase N (AP-N). The best Ang IV mimetics in the series were approximately 20 times less potent than Ang IV as IRAP inhibitors. Furthermore, it was found that the ligands at best exhibited a 140 times lower binding affinity to the membrane-bound IRAP/AT4 receptor than Ang IV. Although the best compounds still exert lower activities than Ang IV, it is notable that these compounds comprise only two amino acid residues and are considerably less peptidic in character than the majority of the Ang IV analogues previously reported as IRAP inhibitors in the literature.
Collapse
|
197
|
Bandala Y, Aviña J, González T, Rivero IA, Juaristi E. Solid phase synthesis of novelα/β-tetrapeptides, electrospray ionization mass spectrometric evaluation of their metal cation complexation behavior, and conformational analysis using density functional theory (DFT). J PHYS ORG CHEM 2008. [DOI: 10.1002/poc.1328] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
198
|
Audie J, Scarlata S. A novel empirical free energy function that explains and predicts protein–protein binding affinities. Biophys Chem 2007; 129:198-211. [PMID: 17600612 DOI: 10.1016/j.bpc.2007.05.021] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2007] [Revised: 05/31/2007] [Accepted: 05/31/2007] [Indexed: 11/22/2022]
Abstract
A free energy function can be defined as a mathematical expression that relates macroscopic free energy changes to microscopic or molecular properties. Free energy functions can be used to explain and predict the affinity of a ligand for a protein and to score and discriminate between native and non-native binding modes. However, there is a natural tension between developing a function fast enough to solve the scoring problem but rigorous enough to explain and predict binding affinities. Here, we present a novel, physics-based free energy function that is computationally inexpensive, yet explanatory and predictive. The function results from a derivation that assumes the cost of polar desolvation can be ignored and that includes a unique and implicit treatment of interfacial water-bridged interactions. The function was parameterized on an internally consistent, high quality training set giving R2=0.97 and Q2=0.91. We used the function to blindly and successfully predict binding affinities for a diverse test set of 31 wild-type protein-protein and protein-peptide complexes (R2=0.79, rmsd=1.2 kcal mol(-1)). The function performed very well in direct comparison with a recently described knowledge-based potential and the function appears to be transferable. Our results indicate that our function is well suited for solving a wide range of protein/peptide design and discovery problems.
Collapse
Affiliation(s)
- Joseph Audie
- Department of Physiology and Biophysics, State University of New York at Stony Brook, Stony, Brook, NY 11794, USA
| | | |
Collapse
|
199
|
Galeazzi R, Martelli G, Marcucci E, Mobbili G, Natali D, Orena M, Rinaldi S. A New Conformationally Restricted Mimetic of Dipeptide EG – Synthesis of an Analogue of FEG. European J Org Chem 2007. [DOI: 10.1002/ejoc.200700300] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
200
|
Scalabrino GA, Hogan N, O'Boyle KM, Slator GR, Gregg DJ, Fitchett CM, Draper SM, Bennett GW, Hinkle PM, Bauer K, Williams CH, Tipton KF, Kelly JA. Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone. Neuropharmacology 2007; 52:1472-81. [PMID: 17418282 DOI: 10.1016/j.neuropharm.2007.02.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2006] [Revised: 02/07/2007] [Accepted: 02/09/2007] [Indexed: 10/23/2022]
Abstract
Thyrotropin-releasing hormone (TRH) displays multiple CNS-mediated actions that have long been recognized to have therapeutic potential in treating a wide range of neurological disorders. Investigations of CNS functions and clinical use of TRH are hindered, however, due to its rapid degradation by TRH-degrading ectoenzyme (TRH-DE). We now report the discovery of a set of first-in-class compounds that display unique ability to both potently inhibit TRH-DE and bind to central TRH receptors with unparalleled affinity. This dual pharmacological activity within one molecular entity was found through selective manipulation of peptide stereochemistry. Notably, the lead compound of this set, L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide (Glp-Asn-Pro-D-Tyr-D-TrpNH(2)), is effective in vivo at producing and potentiating central actions of TRH without evoking release of thyroid-stimulating hormone (TSH). Specifically, this peptide displayed high plasma stability and combined potent inhibition of TRH-DE (K(i) 151 nM) with high affinity binding to central TRH receptors (K(i) 6.8 nM). Moreover, intraperitoneal injection of this peptide mimicked and augmented the effects of TRH on behavioural activity in rat. Analogous to TRH, it also antagonized pentobarbital-induced narcosis when administered intravenously. This discovery provides new opportunities for probing the role of TRH actions in the CNS and a basis for development of novel TRH-based neurotherapeutics.
Collapse
Affiliation(s)
- Gaia A Scalabrino
- School of Biochemistry and Immunology and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|